Health CarePharmaceuticals and Biotechnology
  • Price (EUR)14.65
  • Today's Change-0.385 / -2.56%
  • Shares traded66.35k
  • 1 Year change-40.85%
  • Beta0.7399
Data delayed at least 15 minutes, as of Mar 31 2023 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

  • Revenue in EUR (TTM)278.27m
  • Net income in EUR-151.06m
  • Incorporated1998
  • Employees629.00
  • Location
    MorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
  • Phone+49 89899270
  • Fax+49 8 989927222
  • Websitehttps://www.morphosys.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
BRAIN Biotech AG53.84m-6.76m123.66m307.00--3.90--2.30-0.3095-0.30952.461.450.7095----154,712.60-8.52-10.80-10.67-14.1054.9555.98-12.01-19.88---11.600.00--28.2313.75-32.54--41.35--
Heidelberg Pharma AG18.51m-19.70m216.62m102.00--3.25--11.70-0.5254-0.52540.49611.430.30271.7617.48181,509.00-32.22-51.65-49.60-73.5174.7347.30-106.42-216.542.98-28.410.1934--958.0457.6724.62--8.06--
Northern Data AG16.38m-84.26m285.55m162.00--0.9944--17.44-7.25-7.251.4112.06------101,094.80--20.18--33.1637.2050.93-514.4885.770.301-0.52520.25190.001,059.28485.60440.81------
MorphoSys AG278.27m-151.06m514.51m629.00--3.26--1.85-4.43-4.438.154.610.11242.163.33442,395.90-6.10-10.92-6.88-12.3282.5388.74-54.29-77.843.83-2.550.6832--54.9333.0370.64--2.98--
Eckert & Zieglr Strahln und Mdzntchnk AG213.44m28.61m924.37m945.0031.824.5523.944.331.371.3710.239.590.59512.446.11246,463.008.118.389.6010.1349.6747.8413.6212.772.3453.280.184835.572.445.5262.2027.0840.1724.82
Formycon AG38.98m76.73m1.07bn178.0010.792.5313.7427.576.216.213.3526.460.087161.102.47227,935.7017.17-6.5917.81-7.3931.9729.53197.04-8.862.12--0.0456--20.3516.22-127.42---2.05--
Biotest AG516.10m-32.49m1.47bn2.23k--2.25--2.84-1.64-1.6426.0818.760.44741.453.37231,642.70-2.74-2.63-3.05-2.9824.1825.66-6.12-6.162.50-1.180.6345--0.0976.4250.01---22.75--
Dermapharm Holding SE1.02bn134.24m2.02bn2.56k15.053.818.661.982.502.5019.059.870.72681.4612.11399,834.609.4110.9610.8612.6464.4960.1912.9414.391.289.390.492440.528.6817.01-35.9545.47-12.19--
Data as of Mar 31 2023. Currency figures normalised to MorphoSys AG's reporting currency: Euro EUR
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.